Association of a very high tumor mutational load with increased CD8+and PD-1+T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.

被引：2
|
作者：
Ricciuti, Biagio
Arbour, Kathryn Cecilia
Alessi, Joao Victor Machado
Mahadevan, Navin
Lindsay, James
Sinha, Rileen
Vokes, Natalie I.
Recondo, Gonzalo
Lamberti, Giuseppe
Rizvi, Hira
Leonardi, Giulia Costanza
Plodkowski, Andrew J.
Felt, Kristen
Tolstorukov, Michael
Janne, Pasi A.
Van Allen, Eliezer Mendel
Sholl, Lynette M.
Rodig, Scott J.
Hellmann, Matthew D.
Awad, Mark M.
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Knowledge Syst Grp, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Dept Informat & Analyt, Boston, MA 02115 USA
[6] Dana Farber Canc Inst, ImmunoProfile, Boston, MA 02115 USA
[7] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA
[8] Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA
[9] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9018
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
    Ricciuti, Biagio
    Wang, Xinan
    Alessi, Joao, V
    Rizvi, Hira
    Mahadevan, Navin R.
    Li, Yvonne Y.
    Polio, Andrew
    Lindsay, James
    Umeton, Renato
    Sinha, Rileen
    Vokes, Natalie, I
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Lawrence, Marissa
    Vaz, Victor R.
    Leonardi, Giulia C.
    Plodkowski, Andrew J.
    Gupta, Hersh
    Cherniack, Andrew D.
    Tolstorukov, Michael Y.
    Sharma, Bijaya
    Felt, Kristen D.
    Gainor, Justin F.
    Ravi, Arvind
    Getz, Gad
    Schalper, Kurt A.
    Henick, Brian
    Forde, Patrick
    Anagnostou, Valsamo
    Janne, Pasi A.
    Van Allen, Eliezer M.
    Nishino, Mizuki
    Sholl, Lynette M.
    Christiani, David C.
    Lin, Xihong
    Rodig, Scott J.
    Hellmann, Matthew D.
    Awad, Mark M.
    JAMA ONCOLOGY, 2022, 8 (08) : 1160 - 1168
  • [2] Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels (vol 8, pg 1160, 2022)
    Ricciuti, B.
    Wang, X.
    Alessi, J., V
    JAMA ONCOLOGY, 2022, 8 (11) : 1702 - 1702
  • [3] Mutational landscapes and PD-L1 expression in non-small cell lung cancer.
    Zhang, Kang
    Wang, Guanghui
    Guo, Chao
    Chen, Xinyu
    Zhang, Shiyue
    Wang, Wenjing
    Yao, Ming
    Liu, Angen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Multifactorial Model to Predict Response to PD-(L)1 Blockade in Patients with High PD-L1 Metastatic Non-Small Cell Lung Cancer
    Arbour, K.
    Oprescu, M.
    Hakim, J.
    Rizvi, H.
    Leiserson, M.
    Ginsburg, M.
    Plodkowski, A.
    Sauter, J.
    Preeshagul, I.
    Gillett, S.
    Rosenfield, P.
    Mackey, L.
    Dudik, M.
    Hellmann, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S290
  • [5] The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer
    Ito, Kentaro
    Miura, Satoru
    Sakaguchi, Tadashi
    Murotani, Kenta
    Horita, Nobuyuki
    Akamatsu, Hiroaki
    Uemura, Kohei
    Morita, Satoshi
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 128 : 113 - 119
  • [6] Association of PD-L1 protein expression and TMB in non-small cell lung cancer.
    Chen, Yaru
    Zhou, Yanqing
    Xu, Yun
    Zhang, Xiaoni
    Xu, Mingyan
    Melancon, Charles E.
    Chen, Shifu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade
    Zhang, Xinmu
    Zhang, Li
    JAMA ONCOLOGY, 2023, 9 (04) : 569 - 570
  • [8] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [9] Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
    Kim, H.
    Kwon, H. J. K.
    Kim, E. S. K.
    Han, Y. B.
    Lee, J.
    Kim, S. H.
    Kim, Y. J.
    Lee, J.
    Chung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S470 - S470
  • [10] Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression
    Barba Joaquin, A.
    Mosquera, J.
    Riudavets Melia, M.
    Gomez-Randulfe, M. I.
    Garcia Campelo, M. R.
    Sullivan, I.
    Serra Lopez, J.
    Aguado, M.
    Piedra, A.
    Majem, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1081 - S1081
12345